Document Detail

Daclizumab use in patients with pediatric multiple sclerosis.
MedLine Citation:
PMID:  22232346     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon.
OBJECTIVE: To report the use of daclizumab in pediatric-onset MS.
DESIGN: Case series.
SETTING: Two comprehensive pediatric MS centers. Patients  Seven patients with pediatric-onset MS with clinical and magnetic resonance imaging disease activity despite first-line disease-modifying therapy. Intervention  Intravenous daclizumab, 1 mg/kg monthly.
MAIN OUTCOME MEASURES: Annualized relapse rates, Expanded Disability Status Scale scores, contrast-enhancing lesions, and adverse effects.
RESULTS: Treatment with daclizumab, primarily combined with interferon, was associated with reductions in annualized relapse rates and contrast-enhancing lesions and with reduction or stabilization of Expanded Disability Status Scale scores in each patient. However, 4 patients had relapses and new contrast-enhancing lesions during daclizumab treatment. No significant adverse effects occurred.
CONCLUSION: Daclizumab may be a safe and at least partially effective treatment option for patients with pediatric-onset MS with disease activity despite first-line disease-modifying therapy.
Mark P Gorman; Jan-Mendelt Tillema; Annika M Ciliax; Charles R G Guttmann; Tanuja Chitnis
Related Documents :
12409756 - Velopharyngeal surgery: a prospective randomized study of pharyngeal flaps and sphincte...
8720406 - A new method using top views of the spine to predict the progression of curves in idiop...
6340156 - The top view for analysis of scoliosis progression.
1547256 - A questionnaire survey of attitudes and concerns of three professional groups involved ...
9051156 - Use of mental health resources in the treatment of adult out-patients with no diagnosab...
24406026 - Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischem...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of neurology     Volume:  69     ISSN:  1538-3687     ISO Abbreviation:  Arch. Neurol.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  78-81     Citation Subset:  AIM; IM    
Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, ACC-708, 55 Fruit St, Boston, MA 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder.
Next Document:  Impact of inflammation on brain volume in multiple sclerosis.